Evotec Receives $5M Milestone Payment from Bristol Myers Following FDA Approval of New Drug Application
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 12 2025
0mins
Source: SeekingAlpha
Milestone Payment: Evotec SE has received a $5 million milestone payment from Bristol Myers Squibb following the FDA's acceptance of an investigational new drug application related to their partnership.
Drug Development: The drug candidate, a cereblon E3 ligase modulator, is set to enter Phase 1 clinical trials in 2026 as part of the collaboration between Evotec and Bristol Myers Squibb.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EVO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EVO
Wall Street analysts forecast EVO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EVO is 6.00 USD with a low forecast of 5.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
2 Buy
0 Hold
1 Sell
Moderate Buy
Current: 3.520
Low
5.00
Averages
6.00
High
7.00
Current: 3.520
Low
5.00
Averages
6.00
High
7.00
About EVO
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
DaVita Reports Strong Q4 Earnings, Shares Surge 21.7%
- Strong Earnings Report: DaVita's Q4 earnings per share of $3.40 exceeded analyst expectations of $3.16, demonstrating robust profitability that enhances market confidence in the company's future performance.
- Sales Beat Estimates: The company reported quarterly sales of $3.620 billion, surpassing the analyst consensus of $3.497 billion, indicating strong competitive positioning and a rebound in customer demand that is expected to drive future revenue growth.
- Significant Stock Surge: DaVita's shares jumped 21.7% to $135.26 on Tuesday, reflecting a positive investor reaction to the financial results, which may attract further institutional interest in the stock.
- Price Target Increase: Barclays raised its price target for DaVita from $143 to $158, indicating analysts' optimistic outlook on the company's growth potential, which could further propel the stock price upward.
See More
Amgen Acquires Dark Blue Therapeutics for Up to $840 Million
- Acquisition Value: Amgen's acquisition of Dark Blue Therapeutics for up to $840 million, including upfront payments and future milestones, underscores the company's strong commitment to investing in oncology drug development.
- Candidate Drug Progress: Dark Blue's lead candidate, DBT 3757, is currently undergoing IND-enabling studies for acute myeloid leukemia and acute lymphoblastic leukemia, which is expected to add significant new options to Amgen's oncology portfolio.
- R&D Integration: Amgen plans to integrate Dark Blue into its existing research organization, further enhancing its early oncology discovery capabilities and propelling MLLT1/3-targeting medicines into clinical investigation, aimed at improving treatment outcomes for AML patients.
- Market Reaction: Following the acquisition announcement, Amgen's stock rose by 2.89% to $339.71, approaching its 52-week high of $346.38, reflecting positive market sentiment regarding the acquisition.
See More
European Market Attracts Dividend Stock Investors Amid 17% Annual Return
- Market Performance: The STOXX Europe 600 Index is projected to achieve an annual return of nearly 17% in 2025, attracting investors to dividend stocks, which indicates a robust economic environment and a growing demand for steady income.
- Dividend Stock Selection: Among the top ten dividend stocks, d'Amico International Shipping boasts a yield of 10.26%, highlighting its appeal in the market and potentially attracting investors seeking high returns.
- Tenaris Financial Overview: With a market cap of €17.49 billion, Tenaris generates $11.26 billion from its Tubes segment in 2025, and although its dividend yield stands at 4.1%, recent buybacks totaling $588 million may enhance shareholder value.
- Banking Sector Dynamics: Liechtensteinische Landesbank, valued at CHF 2.65 billion, offers a dividend yield of 3.2% with a payout ratio of 50.8%, indicating earnings coverage and reflecting a solid foundation amidst strategic leadership transitions.
See More
NBI Revises EVO ETF Reinvested Distribution to $2.50 per Unit
- Distribution Adjustment: NBI announced a revision of the reinvested distribution amount for the Evovest Global Equity ETF (EVO ETF) to $2.50 per unit for 2025, replacing the previous announcement from December 18, 2025, ensuring investors receive the most current income information.
- Distribution Stability: Despite the adjustment in distribution amount, the ex-dividend, record, and payable dates remain unchanged, indicating NBI's commitment to transparency and stability in fund management, aimed at enhancing investor confidence.
- Asset Management Scale: As of September 30, 2025, NBI's assets under management exceeded $105 billion, and this distribution adjustment further solidifies its position in the Canadian investment management market, attracting more investor attention to its products.
- Investor Education Commitment: NBI is dedicated to providing diverse investment solutions and offers professional advice through its advisory services team, helping investors build portfolios tailored to their financial needs, reflecting its keen insight into client demands.
See More
Top European Dividend Stocks Analysis: Yields Exceeding 5%
- Dividend Stock Selection: As the STOXX Europe 600 Index approaches record highs, investors are increasingly focused on dividend stocks, particularly those with stable cash flows like Zurich Insurance (4.09% yield) and Telekom Austria (4.44% yield), indicating a market preference for reliable income.
- Market Performance: Etablissements Maurel & Prom, with a market cap of €1.10 billion, offers a 5.6% dividend yield; however, its unstable payment history over seven years necessitates cautious evaluation of future cash flows and dividend sustainability by investors.
- Banking Sector Dynamics: Sparebanken Møre, valued at NOK 5.80 billion, presents a 5.3% dividend yield, yet declining net income and interest income raise concerns about future dividend sustainability, reflecting a cautious market sentiment towards banking stocks.
- Industry Trends: With growing investor interest in high-dividend stocks, the demand for stable cash flows and strong balance sheets is becoming increasingly evident, which may influence future investment strategies and market liquidity.
See More
Evotec Receives $5M Milestone Payment from Bristol Myers Following FDA Approval of New Drug Application
Milestone Payment: Evotec SE has received a $5 million milestone payment from Bristol Myers Squibb following the FDA's acceptance of an investigational new drug application related to their partnership.
Drug Development: The drug candidate, a cereblon E3 ligase modulator, is set to enter Phase 1 clinical trials in 2026 as part of the collaboration between Evotec and Bristol Myers Squibb.
See More
DaVita Reports Strong Q4 Earnings, Shares Surge 21.7%
- Strong Earnings Report: DaVita's Q4 earnings per share of $3.40 exceeded analyst expectations of $3.16, demonstrating robust profitability that enhances market confidence in the company's future performance.
- Sales Beat Estimates: The company reported quarterly sales of $3.620 billion, surpassing the analyst consensus of $3.497 billion, indicating strong competitive positioning and a rebound in customer demand that is expected to drive future revenue growth.
- Significant Stock Surge: DaVita's shares jumped 21.7% to $135.26 on Tuesday, reflecting a positive investor reaction to the financial results, which may attract further institutional interest in the stock.
- Price Target Increase: Barclays raised its price target for DaVita from $143 to $158, indicating analysts' optimistic outlook on the company's growth potential, which could further propel the stock price upward.
See More
Amgen Acquires Dark Blue Therapeutics for Up to $840 Million
- Acquisition Value: Amgen's acquisition of Dark Blue Therapeutics for up to $840 million, including upfront payments and future milestones, underscores the company's strong commitment to investing in oncology drug development.
- Candidate Drug Progress: Dark Blue's lead candidate, DBT 3757, is currently undergoing IND-enabling studies for acute myeloid leukemia and acute lymphoblastic leukemia, which is expected to add significant new options to Amgen's oncology portfolio.
- R&D Integration: Amgen plans to integrate Dark Blue into its existing research organization, further enhancing its early oncology discovery capabilities and propelling MLLT1/3-targeting medicines into clinical investigation, aimed at improving treatment outcomes for AML patients.
- Market Reaction: Following the acquisition announcement, Amgen's stock rose by 2.89% to $339.71, approaching its 52-week high of $346.38, reflecting positive market sentiment regarding the acquisition.
See More
European Market Attracts Dividend Stock Investors Amid 17% Annual Return
- Market Performance: The STOXX Europe 600 Index is projected to achieve an annual return of nearly 17% in 2025, attracting investors to dividend stocks, which indicates a robust economic environment and a growing demand for steady income.
- Dividend Stock Selection: Among the top ten dividend stocks, d'Amico International Shipping boasts a yield of 10.26%, highlighting its appeal in the market and potentially attracting investors seeking high returns.
- Tenaris Financial Overview: With a market cap of €17.49 billion, Tenaris generates $11.26 billion from its Tubes segment in 2025, and although its dividend yield stands at 4.1%, recent buybacks totaling $588 million may enhance shareholder value.
- Banking Sector Dynamics: Liechtensteinische Landesbank, valued at CHF 2.65 billion, offers a dividend yield of 3.2% with a payout ratio of 50.8%, indicating earnings coverage and reflecting a solid foundation amidst strategic leadership transitions.
See More
NBI Revises EVO ETF Reinvested Distribution to $2.50 per Unit
- Distribution Adjustment: NBI announced a revision of the reinvested distribution amount for the Evovest Global Equity ETF (EVO ETF) to $2.50 per unit for 2025, replacing the previous announcement from December 18, 2025, ensuring investors receive the most current income information.
- Distribution Stability: Despite the adjustment in distribution amount, the ex-dividend, record, and payable dates remain unchanged, indicating NBI's commitment to transparency and stability in fund management, aimed at enhancing investor confidence.
- Asset Management Scale: As of September 30, 2025, NBI's assets under management exceeded $105 billion, and this distribution adjustment further solidifies its position in the Canadian investment management market, attracting more investor attention to its products.
- Investor Education Commitment: NBI is dedicated to providing diverse investment solutions and offers professional advice through its advisory services team, helping investors build portfolios tailored to their financial needs, reflecting its keen insight into client demands.
See More
Top European Dividend Stocks Analysis: Yields Exceeding 5%
- Dividend Stock Selection: As the STOXX Europe 600 Index approaches record highs, investors are increasingly focused on dividend stocks, particularly those with stable cash flows like Zurich Insurance (4.09% yield) and Telekom Austria (4.44% yield), indicating a market preference for reliable income.
- Market Performance: Etablissements Maurel & Prom, with a market cap of €1.10 billion, offers a 5.6% dividend yield; however, its unstable payment history over seven years necessitates cautious evaluation of future cash flows and dividend sustainability by investors.
- Banking Sector Dynamics: Sparebanken Møre, valued at NOK 5.80 billion, presents a 5.3% dividend yield, yet declining net income and interest income raise concerns about future dividend sustainability, reflecting a cautious market sentiment towards banking stocks.
- Industry Trends: With growing investor interest in high-dividend stocks, the demand for stable cash flows and strong balance sheets is becoming increasingly evident, which may influence future investment strategies and market liquidity.
See More
Evotec Receives $5M Milestone Payment from Bristol Myers Following FDA Approval of New Drug Application
Milestone Payment: Evotec SE has received a $5 million milestone payment from Bristol Myers Squibb following the FDA's acceptance of an investigational new drug application related to their partnership.
Drug Development: The drug candidate, a cereblon E3 ligase modulator, is set to enter Phase 1 clinical trials in 2026 as part of the collaboration between Evotec and Bristol Myers Squibb.
See More
